Erectile Dysfunction Drugs Market Size Regional Analysis, Key Players, Opportunities and Forecast to 2027
Erectile Dysfunction Drugs Market 2021
According to Market Research Future (MRFR), the global erectile dysfunction drugs market is expected to reach a market value of USD 2930 million with a CAGR of 3.5% from 2019 to 2025 (forecast period). The report introspects the opportunities, challenges, cost structure, and recent developments pertaining to the erectile dysfunction drugs market in the report and the impact of the COVID-19 on these facets.
Erectile dysfunction is also referred to as impotence and is characterized by an inability to build up or maintain a penile erection during sexual intercourse. Penis erection involves a hydraulic effect resulting from the entry and retention of blood into spongy bodies within the penis. Sexual arousal is responsible for the initiation of this process, indicated by the brain-to-penile nerve impulse mechanism. The causes of erectile dysfunction include adverse effects of medications, cavernosal disorders, neurogenic disorders, aging, psychological factors, multiple sclerosis and diabetes, and lifestyle changes.
Get a Sample Request @ https://www.marketresearchfuture.com/sample_request/1313
Major Key Players:
Pfizer Inc. (U.S), Bayer AG (Germany), Eli Lily & Co. (U.S), Dong–A Pharmaceutical Co. Ltd. (South Korea), Apricus Biosciences Inc.(U.S), S.K. Chemicals Co. Ltd. (South Korea), Apricus Biosciences Inc. (U.S), Cristalia Produtos Quimicos Farmaceuticos Ltd. (Brazil), Dong-A Pharmaceutical Co. Ltd., (South Korea), Meda Pharmaceuticals, Inc. (U.S), Vivus, Inc. (U.S), and others are some of the prominent players at the forefront of competition in the global Erectile Dysfunction Drugs Market Size and are profiled in MRFR Analysis.
Market Segmentation
The global market for erectile dysfunction drugs has been segmented based on drug and end-user.
Based on drug, the global market for erectile dysfunction drugs has been bifurcated into viagra (sildenafil citrate), cialis (tadalafil), stendra/spedra (avanafil), staxyn/levitra (vardenafil), vitaros (alprostadil cream), zydena (udenafil), and others. The viagra segment is expected to hold a significant market share as the first approved oral treatment for erectile dysfunction approved by the Food and Drug Administration (FDA). In 1998, Pfizer launched viagra, which dominates the market for erectile dysfunction. The Cialis segment is projected to be the fastest-growing segment because cialis offers erection for a longer period of time than viagra, cialis lasts up to 18 hours, while viagra lasts just around 4 to 6 hours.
Based on end-user, the global market for erectile dysfunction drugs has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment is projected to be the largest market because it is readily available in retail stores. The hospital pharmacy segment is projected to be the fastest-growing segment as an increasing patient pool due to increased awareness and patient education.
Regional Analysis:
Geographically, the regional Erectile Dysfunction Drugs Market is segmented into America, Europe, Asia Pacific, and the Middle East & Africa.
The Americas account for the major share of the market owing to the presence of patient population, well-developed technology, and high healthcare expenditure. According to University of Wisconsin Hospitals and Clinics Authority, about 5 percent of men that are 40 years old have complete erectile dysfunction, and that number increases to about 15 percent of men at age 70. Mild and moderate erectile dysfunction affects approximately 10 percent of men per decade of life.
Europe holds the major share of the market, which is majorly contributed by Germany, the U.K., and France. According to the UK Health Centre, 50 percent of men that smoke a pack of cigarettes a day have a higher chance of developing erectile dysfunction. Furthermore, as per a study recently presented at the European Association of Urology showed that erectile dysfunction isn’t being treated very often, with only 25.4 percent of men in the being treated for the condition.
Asia Pacific is the fastest growing market owing to rapidly changing healthcare sector, and the presence of huge opportunities for the development of this market. However, the Middle East & Africa has the least share in the market owing to the presence of poor and slow developing countries, especially, in African region. The Middle East holds the major share of the regional market due to well-developed technology and high spending.
Access Full Report Details and Order this Premium Report @ https://www.marketresearchfuture.com/reports/erectile-dysfunction-drugs-market-1313
NOTE: Our Team of Researchers are Studying Covid19 and its Impact on Various Industry Verticals and wherever required we will be considering Covid19 Footprints for Better Analysis of Market and Industries. Cordially get in Touch for More Details.
About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Comments
Post a Comment